Suspected plague outbreak in Russia: public health risk lower than Covid-19
On 1 October, a laboratory worker at the Irkutsk Research Anti-Plague Institute of Siberia died after being diagnosed with pneumonia.…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data were presented comparing Eli…
-
EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis
On 29 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, an indirect treatment comparison evaluated Eli…
-
China expands its manufacturing role for biopharma’s new drugs
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging…
-
FDA hearing: psychedelics launch needs balanced regulation without limiting access
The area of psychedelic therapeutics has been rapidly growing in research and drug development with the advent of classical psychedelics…
-
ERS 2026: obesity, an independent obstruction to biologic-treated asthma
On 7 September at the European Respiratory Society (ERS) 2026 Annual Meeting, investigators from the University of Siena presented their…
-
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
On 7 September, at the European Respiratory Society (ERS) 2026 Annual Meeting, a group of investigators, which included both academic…
-
ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma
On Sunday, September 6, at the European Respiratory Society (ERS) 2026 Annual Meeting, Generate: Biomedicinesinvestigators presented pharmacodynamics and safety results…
-
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD
On September 7, at the 2026 European Respiratory Society (ERS) International Congress in Barcelona, AstraZeneca presented results from an integrated…